Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT
THE PROPOSED PLANNING OF THE SPIN-OFF LISTING OF FOSUN ADGENVAX ON THE STOCK EXCHANGE

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**").

On 28 October 2025, the board of directors of the Company (the "**Board**") has resolved approving the proposed planning of the spin-off listing (the "**Proposed Spin-off Listing**") of Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd* (復星安特金(成都)生物製藥有限公司, "**Fosun Adgenvax**"), a subsidiary of the Company, on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Fosun Adgenvax was established in July 2012. As at the date of this announcement, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.* (上海復星醫藥產業發展有限公司), a subsidiary of the Company, holds 70.08% equity interest in Fosun Adgenvax, and 17 other shareholders hold the remaining 29.92% equity interest. Fosun Adgenvax and its subsidiaries focus on research, development, production and sales of vaccines for human use, having established technical platforms for both bacterial and viral vaccines. As at the date of this announcement, in Chinese mainland (for the purpose of this announcement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the Taiwan Region), its self-developed products, such as rabies vaccine (Vero cell) for human use, rabies vaccine (Vero cell) for human use (freeze dried), trivalent influenza virus lysate vaccine and quadrivalent influenza virus lysate vaccine, have been approved for marketing; its self-developed 13-valent pneumococcal conjugate vaccine (multivalent combinations) is currently in the Phase III clinical trial stage; its self-developed rabies vaccine (human diploid cells) for human use (freeze-dried) and 24-valent pneumococcal polysaccharide conjugate vaccine are both in the Phase I clinical trial stage; and its self-developed 23-valent pneumococcal polysaccharide vaccine has been approved for clinical trial.

Shareholders and potential investors of the Company should note that the Proposed Spin-off Listing is at its preliminary planning stage. The Company will comply with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and make further announcement(s) in connection with the Proposed Spin-off Listing as and when appropriate or required under the Listing Rules. The Company makes no assurance as to the timing, price and completion of the Proposed Spin-off Listing. Accordingly, shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
28 October 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *For identification purpose only*